VJHemOnc is committed to improving our service to you

SOHO 2020 | Immuno-oncology approaches in MDS

VJHemOnc is committed to improving our service to you

Naval Daver

Naval Daver, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, explores the use of immuno-oncology in myelodysplastic syndromes (MDS), including targeted therapies such as IDH inhibitors, FLT3 inhibitors, venetoclax targeting BCL-2, as well as the anti-TIM-3 checkpoint MBG453 evaluated in a Phase III study with azacitidine in patients with MDS (NCT03066648). Dr Daver highlights these agents as a promising future for the treatment and management of patients with myelodysplastic syndromes, and points towards the tumor microenvironment as an important area of understanding for the implementation of immunotherapies and as a factor determining resistance or lack of response to therapeutic agents. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter